Petros Pharmaceuticals, Inc. (PTPI) NASDAQ
0.01
-0.0011(-18.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.01
-0.0011(-18.03%)
Currency In USD
Address
1185 Avenue of the Americas
New York City, NY 10036
United States of America (the)
Phone
973-242-0005
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
First IPO Date
December 02, 2020
| Name | Title | Pay | Year Born |
| Mitchell S. Arnold | Vice President of Finance & Chief Accounting Officer | 303,523 | 1964 |
| Fady Boctor | President & Chief Commercial Officer | 406,254 | 1978 |
| Joshua N. Silverman | Executive Chairman of the Board | 521,250 | 1970 |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.